Diabetische Nephropathie

ZUSAMMENFASSUNG

Der Einfluss des Geschlechts auf die Prävalenz, das Auftreten und den Verlauf vieler Erkrankungen ist tiefgreifend. In den meisten Fällen wird ein bestimmtes Geschlecht als Risikofaktor für die Genese und Progression der Krankheit angesehen. Dies ist bei der diabetischen Nephropathie (DN) nicht ganz so eindeutig, deren Entwicklung und Schweregrad von vielen Faktoren wie dem Typ und der Dauer des Diabetes mellitus, der Blutzucker- und Blutdruckeinstellung sowie biologisch-genetischen Risikofaktoren abhängen. Insbesondere die Tatsache, dass die Sexualhormonspiegel, die an der Pathophysiologie der Nieren beteiligt zu sein scheinen, durch den Diabetes mellitus selbst dramatisch beeinflusst werden, verdeutlicht die Komplexität der Frage nach den Geschlechtsunterschieden bei DN. Das Hauptziel dieser Übersichtsarbeit ist es, den aktuellen Wissensstand über biologische geschlechtsspezifische Aspekte bei der Genese der DN zusammenzufassen und die Rolle der Sexualhormone zu beleuchten.

Publication History

Article published online:
20 July 2023

• Literatur

• 1 Alicic RZ, Rooney MT, Tuttle KR. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clin J Am Soc Nephrol 2017; 12: 2032-2045 DOI: 10.2215/CJN.11491116.
• 2 Ioannou K. Diabetic nephropathy: is it always there? Assumptions, weaknesses and pitfalls in the diagnosis. Hormones (Athens) 2017; 16: 351-361 DOI: 10.14310/horm.2002.1755.
• 3 Sagoo MK, Gnudi L. Diabetic Nephropathy: An Overview. Methods Mol Biol 2020; 2067: 3-7 DOI: 10.1007/978-1-4939-9841-8_1.
• 4 Qi C, Mao X, Zhang Z. et al Classification and Differential Diagnosis of Diabetic Nephropathy. J Diabetes Res 2017; 2017: 8637138 DOI: 10.1155/2017/8637138.
• 5 Najafian B, Alpers CE, Fogo AB. Pathology of human diabetic nephropathy. Contrib Nephrol 2011; 170: 36-47 DOI: 10.1159/000324942.
• 6 Wolf G, Ritz E. Diabetic nephropathy in type 2 diabetes prevention and patient management. J Am Soc Nephrol 2003; 14: 1396-1405 DOI: 10.1097/01.asn.0000065639.19190.cf.
• 7 Li R, Chung AC, Dong Y. et al The microRNA miR-433 promotes renal fibrosis by amplifying the TGF-β/Smad3-Azin1 pathway. Kidney Int 2013; 84: 1129-1144 DOI: 10.1038/ki.2013.272.
• 8 Iwano M, Neilson EG. Mechanisms of tubulointerstitial fibrosis. Curr Opin Nephrol Hypertens 2004; 13: 279-284 DOI: 10.1097/00041552-200405000-00003.
• 9 McGill JB, Bell DS. Anemia and the role of erythropoietin in diabetes. J Diabetes Complications 2006; 20: 262-272 DOI: 10.1016/j.jdiacomp.2005.08.001.
• 10 Al-Khoury S, Afzali B, Shah N. et al Diabetes, kidney disease and anaemia: time to tackle a troublesome triad?. Int J Clin Pract 2007; 61: 281-289 DOI: 10.1111/j.1742-1241.2006.01259.x.
• 11 Wolf G, Müller N, Hunger-Battefeld W. et al Hemoglobin concentrations are closely linked to renal function in patients with type 1 or 2 diabetes mellitus. Kidney Blood Press Res 2008; 31: 313-321 DOI: 10.1159/000155230.
• 12 Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol 2012; 23: 1631-1634 DOI: 10.1681/ASN.2011111078.
• 13 Krantz SB. Erythropoietin. Blood 1991; 77: 419-434
• 14 Noguchi CT.. Where the Epo cells are Blood. 2008; 111: 4836-4837 DOI: 10.1182/blood-2008-02-135988.
• 15 Tanaka T, Nangaku M. Recent advances and clinical application of erythropoietin and erythropoiesis-stimulating agents. Exp Cell Res 2012; 318: 1068-1073 DOI: 10.1016/j.yexcr.2012.02.035.
• 16 Vinod PB. Pathophysiology of diabetic nephropathy. Clinical Queries: Nephrology 2012; 01: 121-126 DOI: 10.1016/S2211-9477(12)70005-5.
• 17 Wolf G. New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology. Eur J Clin Invest 2004; 34: 785-796 DOI: 10.1111/j.1365-2362.2004.01429.x.
• 18 Hussain S, Chand Jamali M, Habib A. et al Diabetic kidney disease: An overview of prevalence, risk factors, and biomarkers. Clinical Epidemiology and Global Health 2021; 09: 2-6 DOI: 10.1016/j.cegh.2020.05.016.
• 19 Wolf G, Ziyadeh FN. Molecular mechanisms of diabetic renal hypertrophy. Kidney Int 1999; 56: 393-405 DOI: 10.1046/j.1523-1755.1999.00590.x.
• 20 Kolset SO, Reinholt FP, Jenssen T. Diabetic nephropathy and extracellular matrix. J Histochem Cytochem 2012; 60: 976-986 DOI: 10.1369/0022155412465073.
• 21 Neugarten J, Acharya A, Silbiger SR. Effect of gender on the progression of nondiabetic renal disease: a meta-analysis. J Am Soc Nephrol 2000; 11: 319-329 DOI: 10.1681/ASN.V112319.
• 22 Giandalia A, Giuffrida AE, Gembillo G. et al T. Gender Differences in Diabetic Kidney Disease: Focus on Hormonal, Genetic and Clinical Factors. Int J Mol Sci 2021; 22: 5808 DOI: 10.3390/ijms22115808.
• 23 Piani F, Melena I, Tommerdahl KL. et al Sex-related differences in diabetic kidney disease: A review on the mechanisms and potential therapeutic implications. J Diabetes Complications 2021; 35: 107841 DOI: 10.1016/j.jdiacomp.2020.107841.
• 24 Parving HH, Gall MA, Skøtt P. et al Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients. Kidney Int 1992; 41: 758-762 DOI: 10.1038/ki.1992.118.
• 25 Keane WF, Brenner BM, de Zeeuw D. et al RENAAL Study Investigators. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int 2003; 63: 1499-1507 DOI: 10.1046/j.1523-1755.2003.00885.x.
• 26 Nakano S, Ogihara M, Tamura C. et al Reversed circadian blood pressure rhythm independently predicts endstage renal failure in non-insulin-dependent diabetes mellitus subjects. J Diabetes Complications 1999; 13: 224-231 DOI: 10.1016/s1056-8727(99)00049-5.
• 27 Breyer JA, Bain RP, Evans JK. et al Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. The Collaborative Study Group. Kidney Int 1996; 50: 1651-1658 DOI: 10.1038/ki.1996.481.
• 28 Rossing P, Hougaard P, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study. Diabetes Care 2002; 25: 859-864 DOI: 10.2337/diacare.25.5.859.
• 29 Torffvit O, Agardh CD. The impact of metabolic and blood pressure control on incidence and progression of nephropathy. A 10-year study of 385 type 2 diabetic patients. J Diabetes Complications 2001; 15: 307-513 DOI: 10.1016/s1056-8727(01)00176-3.
• 30 Maahs DM, West NA, Lawrence JM. et al Epidemiology of type 1 diabetes. Endocrinol Metab Clin North Am 2010; 39: 481-497 DOI: 10.1016/j.ecl.2010.05.011.
• 31 Beeson PB. Age and sex associations of 40 autoimmune diseases. Am J Med 1994; 96: 457-462 DOI: 10.1016/0002-9343(94)90173-2.
• 32 Mayer-Davis EJ, Lawrence JM, Dabelea D. et al SEARCH for Diabetes in Youth Study. Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002–2012. N Engl J Med 2017; 376: 1419-1429 DOI: 10.1056/NEJMoa1610187.
• 33 Hamman RF, Bell RA, Dabelea D. et al SEARCH for Diabetes in Youth Study Group. The SEARCH for Diabetes in Youth study: rationale, findings, and future directions. Diabetes Care 2014; 37: 3336-3344 DOI: 10.2337/dc14-0574.
• 34 Shepard BD. Sex differences in diabetes and kidney disease: mechanisms and consequences. Am J Physiol Renal Physiol 2019; 317: F456-F462 DOI: 10.1152/ajprenal.00249.2019.
• 35 Kautzky-Willer A, Harreiter J, Pacini G. Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus. Endocr Rev 2016; 37: 278-316 DOI: 10.1210/er.2015-1137.
• 36 Wannamethee SG, Papacosta O, Lawlor DA. et al Do women exhibit greater differences in established and novel risk factors between diabetes and non-diabetes than men? The British Regional Heart Study and British Women’s Heart Health Study. Diabetologia 2012; 55: 80-87 DOI: 10.1007/s00125-011-2284-4.
• 37 Paul SK, Owusu Adjah ES, Samanta M. et al Comparison of body mass index at diagnosis of diabetes in a multi-ethnic population: A case-control study with matched non-diabetic controls. Diabetes Obes Metab 2017; 19: 1014-1023 DOI: 10.1111/dom.12915.
• 38 Huebschmann AG, Huxley RR, Kohrt WM. et al Sex differences in the burden of type 2 diabetes and cardiovascular risk across the life course. Diabetologia 2019; 62: 1761-1772 DOI: 10.1007/s00125-019-4939-5.
• 39 Leon BM, Maddox TM. Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes 2015; 06: 1246-1258 DOI: 10.4239/wjd.v6.i13.1246.
• 40 Raile K, Galler A, Hofer S. et al Diabetic nephropathy in 27,805 children, adolescents, and adults with type 1 diabetes: effect of diabetes duration, A1C, hypertension, dyslipidemia, diabetes onset, and sex. Diabetes Care 2007; 30: 2523-2528 DOI: 10.2337/dc07-0282.
• 41 Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR. UKPDS Study Group. Risk factors for renal dysfunction in type 2 diabetes: U. K. Prospective Diabetes Study 74. Diabetes 2006; 55: 1832-1839 DOI: 10.2337/db05-1620.
• 42 Orchard TJ, Dorman JS, Maser RE. et al Prevalence of complications in IDDM by sex and duration. Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes 1990; 39: 1116-1124 DOI: 10.2337/diab.39.9.1116.
• 43 Maric C, Sullivan S. Estrogens and the diabetic kidney. Gend Med 2008; 05: S103-S113 DOI: 10.1016/j.genm.2008.03.010.
• 44 Dahlquist G, Källén B. Mortality in childhood-onset type 1 diabetes: a population-based study. Diabetes Care 2005; 28: 2384-2387 DOI: 10.2337/diacare.28.10.2384.
• 45 Harvey JN. The influence of sex and puberty on the progression of diabetic nephropathy and retinopathy. Diabetologia 2011; 54: 1943-1945 DOI: 10.1007/s00125-011-2185-6.
• 46 Amin R, Schultz C, Ong K. et al Oxford Regional Prospective Study. Low IGF-I and elevated testosterone during puberty in subjects with type 1 diabetes developing microalbuminuria in comparison to normoalbuminuric control subjects: the Oxford Regional Prospective Study. Diabetes Care 2003; 26: 1456-1461 DOI: 10.2337/diacare.26.5.1456.
• 47 Maric C, Forsblom C, Thorn L. et al FinnDiane Study Group. Association between testosterone, estradiol and sex hormone binding globulin levels in men with type 1 diabetes with nephropathy. Steroids 2010; 75: 772-778 DOI: 10.1016/j.steroids.2010.01.011.
• 48 Harjutsalo V, Maric-Bilkan C, Forsblom C. et al FinnDiane Study Group. Age at menarche and the risk of diabetic microvascular complications in patients with type 1 diabetes. Diabetologia 2016; 59: 472-480 DOI: 10.1007/s00125-015-3816-0.
• 49 Zhang L, Krzentowski G, Albert A. et al Factors predictive of nephropathy in DCCT Type 1 diabetic patients with good or poor metabolic control. Diabet Med 2003; 20: 580-585 DOI: 10.1046/j.1464-5491.2003.00986.x.
• 50 Silbiger S, Neugarten J. Gender and human chronic renal disease. Gend Med 2008; 05: S3-S10 DOI: 10.1016/j.genm.2008.03.002.
• 51 Kautzky-Willer A, Handisurya A.. Metabolic diseases and associated complications: sex and gender matter!. Eur J Clin Invest 2009; 39: 631-648 DOI: 10.1111/j.1365-2362.2009.02161.x.
• 52 Sibley SD, Thomas W, de Boer I. et al Gender and elevated albumin excretion in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort: role of central obesity. Am J Kidney Dis 2006; 47: 223-232 DOI: 10.1053/j.ajkd.2005.10.021.
• 53 Looker HC, Krakoff J, Funahashi T. et al Adiponectin concentrations are influenced by renal function and diabetes duration in Pima Indians with type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 4010-7 DOI: 10.1210/jc.2003-031916.
• 54 Crook ED, Patel SR. Diabetic nephropathy in African-American patients. Curr Diab Rep 2004; 04: 455-461 DOI: 10.1007/s11892-004-0056-y.
• 55 Peters V, Zschocke J, Schmitt CP. Carnosinase, diabetes mellitus and the potential relevance of carnosinase deficiency. J Inherit Metab Dis 2018; 41: 39-47 DOI: 10.1007/s10545-017-0099-2.
• 56 Maric-Bilkan C. Sex differences in micro- and macro-vascular complications of diabetes mellitus. Clin Sci (Lond) 2017; 131: 833-846 DOI: 10.1042/CS20160998.
• 57 Clotet S, Riera M, Pascual J. et al RAS and sex differences in diabetic nephropathy. Am J Physiol Renal Physiol 2016; 310: F945-F957 DOI: 10.1152/ajprenal.00292.2015.
• 58 Payne AH, Hales DB. Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr Rev 2004; 25: 947-970 DOI: 10.1210/er.2003-0030.
• 59 Gambineri A, Pelusi C. Sex hormones, obesity and type 2 diabetes: is there a link?. Endocr Connect 2019; 08: R1-R9 DOI: 10.1530/EC-18-0450.
• 60 Livingstone C, Collison M. Sex steroids and insulin resistance. Clin Sci (Lond) 2002; 102: 151-166 DOI: 10.1042/cs1020151.
• 61 Yan H, Yang W, Zhou F. et al Estrogen Improves Insulin Sensitivity and Suppresses Gluconeogenesis via the Transcription Factor Foxo1. Diabetes 2019; 68: 291-304 DOI: 10.2337/db18-0638.
• 62 Chang E, Varghese M, Singer K. Gender and Sex Differences in Adipose Tissue. Curr Diab Rep 2018; 18: 69 DOI: 10.1007/s11892-018-1031-3.
• 63 Gyawali P, Martin SA, Heilbronn LK. et al The role of sex hormone-binding globulin (SHBG), testosterone, and other sex steroids, on the development of type 2 diabetes in a cohort of community-dwelling middle-aged to elderly men. Acta Diabetol 2018; 55: 861-872 DOI: 10.1007/s00592-018-1163-6.
• 64 Maric C. Sex, diabetes and the kidney. Am J Physiol Renal Physiol 2009; 296: F680-F688 DOI: 10.1152/ajprenal.90505.2008.
• 65 Cheung KK, Luk AO, So WY. et al Testosterone level in men with type 2 diabetes mellitus and related metabolic effects: A review of current evidence. J Diabetes Investig 2015; 06: 112-123 DOI: 10.1111/jdi.12288.
• 66 Liu J, Liu Z, Sun W. et al Role of sex hormones in diabetic nephropathy. Front Endocrinol 2023: 14 DOI: 10.3389/fendo.2023.1135530